Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and safety of 2‑month aripiprazole IM depot in schizophrenia
jRCT2031260174Phase 1Recruiting
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of aripiprazole in schizophrenia, sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoints: Plasma concentrations of aripiprazole and dehydro-aripiprazole and Pharmacokinetic parameters of aripiprazole and dehydro-aripiprazole. Started Jun 2026; status: recruiting.
02
Drugs
aripiprazole
03
Conditions
schizophrenia
Beyond the preview
Go deeper on jRCT2031260174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260174.